We are live on ! Find out more
LJPC

La Jolla Pharmaceutical Company

Delisted

LJPC was delisted on the 19th of August, 2022.

53 hedge funds and large institutions have $266M invested in La Jolla Pharmaceutical Company in 2015 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 22 increasing their positions, 6 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 6

163% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 8

128% more call options, than puts

Call options by funds: $2.24M | Put options by funds: $981K

44% more capital invested

Capital invested by funds: $184M → $266M (+$81.9M)

33% more funds holding

Funds holding: 4053 (+13)

50% less funds holding in top 10

Funds holding in top 10: 42 (-2)

Holders
53
Holders Change
+13
Holders Change %
+32.5%
% of All Funds
1.43%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
21
Increased
22
Reduced
6
Closed
8
Calls
$2.24M
Puts
$981K
Net Calls
+$1.26M
Net Calls Change
+$1.55M
Name Holding Trade Value Shares
Change
Change in
Stake
TCM
1
Tang Capital Management
California
$65.3M +$10.7M +520,583 +24%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$56.1M +$7.86M +381,459 +20%
Franklin Resources
3
Franklin Resources
California
$24.1M +$1.32M +64,200 +7%
BC
4
Broadfin Capital
New York
$18.6M +$1.15M +56,000 +8%
ACA
5
Avoro Capital Advisors
New York
$15M +$3.1M +150,500 +33%
VAM
6
Visium Asset Management
New York
$15M -$921K -44,700 -7%
BBA
7
Baker Bros. Advisors
New York
$10.1M
Vanguard Group
8
Vanguard Group
Pennsylvania
$9.27M +$575K +27,897 +8%
BFA
9
BlackRock Fund Advisors
California
$7.43M +$5.62M +272,612 +898%
RI
10
RTW Investments
New York
$6.95M -$16.1M -780,547 -73%
PA
11
Perceptive Advisors
New York
$6.2M
BIT
12
BlackRock Institutional Trust
California
$5.19M +$1.79M +86,643 +69%
Morgan Stanley
13
Morgan Stanley
New York
$3.08M +$745K +36,156 +40%
GIM
14
Granahan Investment Management
Massachusetts
$3.04M -$359K -17,430 -12%
State Street
15
State Street
Massachusetts
$2.32M +$1.95M +94,731 New
D.E. Shaw & Co
16
D.E. Shaw & Co
New York
$2.29M -$1.49M -72,479 -44%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$1.65M +$154K +7,450 +12%
PAWC
18
P.A.W. Capital
Connecticut
$1.35M +$309K +15,000 +38%
Deutsche Bank
19
Deutsche Bank
Germany
$1.25M +$224K +10,876 +27%
BGA
20
Belmont Global Advisors
Texas
$1.23M -$2.51M -121,600 -71%
HCM
21
Hollencrest Capital Management
California
$1.1M
CCA
22
Catalyst Capital Advisors
New York
$1.1M +$927K +45,000 New
Bank of New York Mellon
23
Bank of New York Mellon
New York
$1.09M +$918K +44,541 New
Northern Trust
24
Northern Trust
Illinois
$999K +$384K +18,644 +84%
BIM
25
BlackRock Investment Management
Delaware
$992K +$792K +38,448 +1,887%

LJPC Hedge Fund Activity: Q2 2015 in Review

53 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q2 2015, worth a combined $266M — up 44% from $184M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new LJPC positions and 8 closed out — a net gain of 13 holders — while 22 added to existing stakes and 6 trimmed.

The largest buyer was Tang Capital Management, adding an estimated $10.7M. The largest seller was RTW Investments, cutting an estimated $16.1M.

  • 53 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q2 2015, up from 40 in Q1 2015.
  • Funds reported $266M of La Jolla Pharmaceutical Company stock for Q2 2015, up 44% quarter-over-quarter.
  • 21 funds opened new La Jolla Pharmaceutical Company positions in Q2 2015 and 8 closed out, a net change of +13 holders.
  • The largest La Jolla Pharmaceutical Company buyer in Q2 2015 was Tang Capital Management, an estimated $10.7M added.
  • The largest La Jolla Pharmaceutical Company seller in Q2 2015 was RTW Investments, an estimated $16.1M sold.

Based on aggregated 13F filings for Q2 2015.